This study focused on four molecular ddPCR-specific assays designed to identify the most frequent hotspot mutations (IDH1-R132H, IDH1-R132C, IDH2-R140Q, and IDH2-R172K) found in the AML patient cohort. Here, IDH2 is linked to acute myeloid leukemia.